Welcome to our dedicated page for Accelerate Diagnostics news (Ticker: AXDX), a resource for investors and traders seeking the latest updates and insights on Accelerate Diagnostics stock.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) delivers innovative solutions for rapid infectious disease testing through its proprietary diagnostic platforms. This page provides investors and healthcare professionals with essential updates on company developments, financial performance, and technological advancements in antimicrobial susceptibility testing.
Access the latest press releases, earnings reports, and regulatory milestones related to AXDX's FDA-cleared systems. Our curated news collection helps stakeholders track progress in combating antibiotic resistance and improving sepsis management through accelerated diagnostics.
Key updates include product launch announcements, partnership developments, and clinical study results for platforms like the Accelerate Pheno® system. All content is verified through primary sources to ensure accuracy and relevance for investment research and clinical decision-making.
Bookmark this page for streamlined access to Accelerate Diagnostics' official communications. Check back regularly for real-time updates on innovations shaping the future of rapid in vitro diagnostics.
Accelerate Diagnostics (NASDAQ: AXDX) will participate in the William Blair 41st Annual Growth Stock Conference on June 3, 2021, at 12:00 p.m. Central Time. CEO Jack Phillips and CFO Steve Reichling will present virtually, and a live audiocast will be available on the company's investor relations website. The company specializes in in vitro diagnostics, focusing on solutions for antibiotic resistance and sepsis, with its Accelerate Pheno® system providing faster results for antibiotic susceptibility testing.
Accelerate Diagnostics, Inc. (AXDX) announced its Q1 2021 financial results, reporting net sales of $2.5 million, an 8% increase from Q1 2020. The company added 2 contracted instruments, ending with 274 revenue-generating instruments in the U.S. However, instrument revenue fell, while consumables rose by 16%. Gross margins dropped to 36% from 45% due to pandemic-related costs. Net loss was $24.2 million or $0.41 per share. SG&A costs increased to $14.0 million, but adjusted costs decreased. The company closed on the first of three $10.7 million financing tranches.
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) will host a conference call on May 6, 2021, at 4:30 p.m. Eastern Time to discuss its 2021 first quarter financial results. Interested participants can join by phone at +1.877.883.0383, entering Elite Entry Number: 4747452, or listen via webcast at ir.axdx.com. A replay will be accessible via phone and the website until August 6, 2021, and May 27, 2021, respectively. Accelerate Diagnostics focuses on solutions for antibiotic resistance and sepsis through its FDA-cleared systems that expedite antibiotic susceptibility testing.
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) reported a net sales of $3.1 million for Q4 2020, reflecting a 10% decline year-over-year, while full-year sales grew by 20% to $11.2 million. The net loss for Q4 was $18.9 million, resulting in a loss of $0.33 per share. The gross margin for Q4 was 37% compared to 44% in the same quarter of 2019. Despite pandemic-related challenges impacting new instrument placements, the company saw a 63% increase in revenue-generating installed base for 2020. Total cash and equivalents stood at $68.3 million at year-end.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) has scheduled a conference call for February 23, 2021, at 4:30 p.m. Eastern Time, to discuss the financial results for the fourth quarter and full year 2020. The call will provide insights into the company’s performance, focusing on their in vitro diagnostics solutions aimed at combating antibiotic resistance and sepsis. An audio webcast will be available at ir.axdx.com, and a replay will be accessible until May 24, 2021.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2020, at 4:00 p.m. Eastern Time. A live audiocast will be available on the company’s investor relations website, with a replay provided for at least 30 days post-conference.
The company focuses on combating antibiotic resistance and sepsis through its Accelerate Pheno® system and Accelerate PhenoTest® BC kit, delivering phenotypic antibiotic susceptibility results in approximately 7 hours.
Accelerate Diagnostics (NASDAQ: AXDX) reported preliminary financial results for Q4 and full year 2020, highlighting a total revenue of approximately $3.1 million for Q4, down from $3.5 million year-over-year, but up to $11.2 million for the full year compared to $9.3 million in 2019. The company placed 45 new instruments in Q4, raising the total to 268 in the U.S., with a backlog of 133 instruments. Gross margin for 2020 is expected at 40%, with net cash used around $41 million, leaving a cash balance of $100 million post-financing. Management remains optimistic about 2021 sales and product launches.
Accelerate Diagnostics (AXDX) reported third-quarter 2020 revenues of $3.6 million, a 57% increase from the previous year. The company ended the quarter with 223 live revenue-generating Pheno instruments in the U.S. However, gross margin fell to 36% due to pandemic-related manufacturing impacts. Year-to-date net sales reached $8.1 million, a 40% rise compared to 2019. The net loss for the quarter was $18.8 million, or $0.33 per share. Cash and equivalents stood at $77.5 million. The company received FDA approvals for key product enhancements, which are expected to stimulate customer interest.
Accelerate Diagnostics, Inc. will host a virtual Investor Product Demo Day on October 20, 2020, at 11:00 a.m. Eastern Time. This event offers insights into the Company's product strategy and features live demonstrations and a Q&A with CEO Jack Phillips. Pre-registration is required by October 19, 2020. Additionally, a conference call reviewing the third quarter financial results is scheduled for November 5, 2020, at 4:30 p.m. Eastern Time.
Accelerate Diagnostics (NASDAQ:AXDX) has received FDA clearance for enhancements to its Accelerate Pheno® system. This upgrade improves antimicrobial susceptibility testing (AST) performance, particularly for treating Pseudomonas aeruginosa infections. The new tests expand the system's AST menu, aiding clinicians in personalized patient care. CEO Jack Phillips emphasized the company's commitment to continual improvement and announced upcoming product releases, including the Accelerate PhenoAST BC GN kit. These advancements aim to reduce testing time significantly, improving patient outcomes.
